Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.

Halogen bonding has recently experienced a renaissance, gaining increased recognition as a useful molecular interaction in the life sciences. Halogen bonds are favorable, fairly directional interactions between an electropositive region on the halogen (the σ-hole) and a number of different nucleophilic interaction partners. Some aspects of halogen bonding are not yet understood well enough to take full advantage of its potential in drug discovery. We describe and present the concept of halogen-enriched fragment libraries. These libraries consist of unique chemical probes, facilitating the identification of favorable halogen bonds by sharing the advantages of classical fragment-based screening. Besides providing insights into the nature and applicability of halogen bonding, halogen-enriched fragment libraries provide smart starting points for hit-to-lead evolution.

[1]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[2]  G. Klebe,et al.  More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin. , 2009, Journal of molecular biology.

[3]  Pavel Hobza,et al.  Br···O Complexes as Probes of Factors Affecting Halogen Bonding: Interactions of Bromobenzenes and Bromopyrimidines with Acetone. , 2009, Journal of chemical theory and computation.

[4]  J. Murray,et al.  σ-hole bonding: molecules containing group VI atoms , 2007 .

[5]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[6]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[7]  Pavel Hobza,et al.  Investigations into the Nature of Halogen Bonding Including Symmetry Adapted Perturbation Theory Analyses. , 2008, Journal of chemical theory and computation.

[8]  Christopher A Lepre,et al.  Practical aspects of NMR-based fragment screening. , 2011, Methods in enzymology.

[9]  L. Poppe,et al.  Fragment based drug discovery: practical implementation based on ¹⁹F NMR spectroscopy. , 2012, Journal of medicinal chemistry.

[10]  M. Hennig,et al.  Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. , 2012, Topics in current chemistry.

[11]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[12]  L Laaksonen,et al.  A graphics program for the analysis and display of molecular dynamics trajectories. , 1992, Journal of molecular graphics.

[13]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[14]  G. Sheldrick,et al.  The magic triangle goes MAD: experimental phasing with a bromine derivative , 2010, Acta crystallographica. Section D, Biological crystallography.

[15]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[16]  Timothy Clark,et al.  3D-QSAR Based on Quantum-Chemical Molecular Fields: Toward an Improved Description of Halogen Interactions , 2012, J. Chem. Inf. Model..

[17]  R E Hubbard,et al.  Experimental and computational mapping of the binding surface of a crystalline protein. , 2001, Protein engineering.

[18]  J. K. Stille,et al.  The Palladium-Catalyzed Cross-Coupling Reactions of Organotin Reagents with Organic Electrophiles , 1986 .

[19]  Stephen K. Burley,et al.  Fragment‐based Lead Discovery and Optimization Using X‐Ray Crystallography, Computational Chemistry, and High‐throughput Organic Synthesis , 2006 .

[20]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[21]  Y. Shao,et al.  Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. , 2012, Journal of medicinal chemistry.

[22]  Akira Suzuki,et al.  Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995–1998 , 1999 .

[23]  T Neumann,et al.  SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.

[24]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[25]  Peter Murray-Rust,et al.  Angular preferences of intermolecular forces around halogen centers: preferred directions of approach of electrophiles and nucleophiles around carbon-halogen bond , 1986 .

[26]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Kevin E. Riley,et al.  σ-Holes, π-holes and electrostatically-driven interactions , 2012, Journal of Molecular Modeling.

[28]  S. F. Boys,et al.  The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors , 1970 .

[29]  Jean-Louis Reymond,et al.  Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17 , 2012, J. Chem. Inf. Model..

[30]  Doriano Fabbro,et al.  7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes , 2011, Journal of medicinal chemistry.

[31]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[32]  E. Negishi,et al.  Selective carbon-carbon bond formation via transition metal catalysis. 3. A highly selective synthesis of unsymmetrical biaryls and diarylmethanes by the nickel- or palladium-catalyzed reaction of aryl- and benzylzinc derivatives with aryl halides , 1977 .

[33]  Stefano Forli,et al.  Crystallographic Fragment‐Based Drug Discovery: Use of a Brominated Fragment Library Targeting HIV Protease , 2014, Chemical biology & drug design.

[34]  Daniel Rauh,et al.  Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. , 2013, Journal of medicinal chemistry.

[35]  Stefan Güssregen,et al.  Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. , 2009, Angewandte Chemie.

[36]  F. Guthrie,et al.  XXVIII.—On the iodide of iodammonium , 1863 .

[37]  S. Grimme.  Improved second-order Møller–Plesset perturbation theory by separate scaling of parallel- and antiparallel-spin pair correlation energies , 2003 .

[38]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[39]  Jian Jin,et al.  Small-molecule ligands of methyl-lysine binding proteins. , 2011, Journal of medicinal chemistry.

[40]  P Shing Ho,et al.  Halogen bonds as orthogonal molecular interactions to hydrogen bonds. , 2009, Nature chemistry.

[41]  M. Mayer,et al.  Structural basis for AMPA receptor activation and ligand selectivity: crystal structures of five agonist complexes with the GluR2 ligand-binding core. , 2002, Journal of molecular biology.

[42]  John P. Wolfe,et al.  Rational Development of Practical Catalysts for Aromatic Carbon−Nitrogen Bond Formation , 1998 .

[43]  P. S. Ho,et al.  Assaying the Energies of Biological Halogen Bonds , 2011 .

[44]  E. Negishi,et al.  Highly general stereo-, regio-, and chemo-selective synthesis of terminal and internal conjugated enynes by the Pd-catalysed reaction of alkynylzinc reagents with alkenyl halides , 1977 .

[45]  W. L. Jorgensen,et al.  Structure‐Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV‐1 Reverse Transcriptase , 2014, Chemical biology & drug design.

[46]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[47]  Marcelo Zaldini Hernandes,et al.  Halogen atoms in the modern medicinal chemistry: hints for the drug design. , 2010, Current drug targets.

[48]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[49]  Pierangelo Metrangolo,et al.  Halogen bonding in supramolecular chemistry. , 2008, Angewandte Chemie.

[50]  A. Polonskaia,et al.  Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[51]  Weiliang Zhu,et al.  Halogen bonding--a novel interaction for rational drug design? , 2009, Journal of medicinal chemistry.

[52]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Markus O. Zimmermann,et al.  Targeting Histidine Side Chains in Molecular Design through Nitrogen-Halogen Bonds , 2013, J. Chem. Inf. Model..

[54]  Olan Dolezal,et al.  Parallel Screening of Low Molecular Weight Fragment Libraries , 2013, Journal of biomolecular screening.

[55]  Kasper Harpsøe,et al.  Intersubunit Bridge Formation Governs Agonist Efficacy at Nicotinic Acetylcholine α4β2 Receptors , 2011, The Journal of Biological Chemistry.

[56]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[57]  Stephen W. Fesik,et al.  Fragment-based drug discovery using NMR spectroscopy , 2013, Journal of biomolecular NMR.

[58]  S. Curry,et al.  Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin , 2011, BMC Structural Biology.

[59]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[60]  Pierangelo Metrangolo,et al.  Definition of the halogen bond (IUPAC Recommendations 2013) , 2013 .

[61]  Frank H. Allen,et al.  The Nature and Geometry of Intermolecular Interactions between Halogens and Oxygen or Nitrogen , 1996 .

[62]  E. Segala,et al.  New Mutations in the Mycobacterial ATP Synthase: New Insights into the Binding of the Diarylquinoline TMC207 to the ATP Synthase C-Ring Structure , 2012, Antimicrobial Agents and Chemotherapy.

[63]  Markus O. Zimmermann,et al.  Using halogen bonds to address the protein backbone: a systematic evaluation , 2012, Journal of Computer-Aided Molecular Design.

[64]  Vicki L. Nienaber,et al.  Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.

[65]  Wolfgang Albrecht,et al.  Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. , 2012, Nature chemical biology.

[66]  Kenneth D Anderson,et al.  Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants. , 2009, Bioorganic & Medicinal Chemistry Letters.

[67]  Pavel Hobza,et al.  The relative roles of electrostatics and dispersion in the stabilization of halogen bonds. , 2013, Physical chemistry chemical physics : PCCP.

[68]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Damian Szklarczyk,et al.  Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing , 2011, Chemistry & biology.

[70]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[71]  Peter Kuhn,et al.  The genesis of high-throughput structure-based drug discovery using protein crystallography. , 2002, Current opinion in chemical biology.

[72]  Jan M. L. Martin,et al.  Halogen Bonds: Benchmarks and Theoretical Analysis. , 2013, Journal of chemical theory and computation.

[73]  N. A. Sörensen,et al.  The Structure of Bromine 1,4-Dioxanate. , 1954 .

[74]  Pavel Hobza,et al.  Benchmark Calculations of Noncovalent Interactions of Halogenated Molecules. , 2012, Journal of chemical theory and computation.

[75]  Markus O. Zimmermann,et al.  Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 , 2012, Journal of the American Chemical Society.

[76]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[77]  L. Johnson,et al.  Halogen bonds form the basis for selective P-TEFb inhibition by DRB. , 2010, Chemistry & biology.

[78]  Weiliang Zhu,et al.  Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. , 2011, Journal of medicinal chemistry.

[79]  Timothy Clark,et al.  Halogen bonding: the σ-hole , 2007 .

[80]  William L Jorgensen,et al.  Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. , 2012, Journal of the American Chemical Society.

[81]  Brian W Matthews,et al.  Halogenated benzenes bound within a non-polar cavity in T4 lysozyme provide examples of I...S and I...Se halogen-bonding. , 2009, Journal of molecular biology.

[82]  Michèle N Schulz,et al.  Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.

[83]  Timothy Clark,et al.  Halogen bonding: an electrostatically-driven highly directional noncovalent interaction. , 2010, Physical chemistry chemical physics : PCCP.

[84]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[85]  S. Grimme,et al.  A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. , 2010, The Journal of chemical physics.

[86]  Lorenz C. Blum,et al.  Chemical space as a source for new drugs , 2010 .

[87]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[88]  M. Plesset,et al.  Note on an Approximation Treatment for Many-Electron Systems , 1934 .

[89]  E. Negishi.  Palladium- or nickel-catalyzed cross coupling. A new selective method for carbon-carbon bond formation , 1982 .

[90]  Peter Politzer,et al.  An overview of halogen bonding , 2007, Journal of molecular modeling.

[91]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[92]  J. Stephen Binkley,et al.  Theoretical models incorporating electron correlation , 2009 .

[93]  G. C. Fu,et al.  Palladium-catalyzed coupling reactions of aryl chlorides. , 2002, Angewandte Chemie.

[94]  M. Hann,et al.  Finding the sweet spot: the role of nature and nurture in medicinal chemistry , 2012, Nature Reviews Drug Discovery.

[95]  J. Kuriyan,et al.  Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp , 2008, Proceedings of the National Academy of Sciences.

[96]  Elizabeth A Lunney,et al.  Kinase inhibition that hinges on halogen bonds. , 2011, Chemistry & biology.

[97]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[98]  François Diederich,et al.  Systematic investigation of halogen bonding in protein-ligand interactions. , 2011, Angewandte Chemie.

[99]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[100]  P. Nordlund,et al.  Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination , 2006, Proceedings of the National Academy of Sciences.

[101]  Pierangelo Metrangolo,et al.  Halogen bonding based recognition processes: a world parallel to hydrogen bonding. , 2005, Accounts of chemical research.

[102]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[103]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[104]  D. Ringe,et al.  Enzyme crystal structure in a neat organic solvent. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Jindřich Fanfrlík,et al.  Halogen bond tunability I: the effects of aromatic fluorine substitution on the strengths of halogen-bonding interactions involving chlorine, bromine, and iodine , 2011, Journal of molecular modeling.

[106]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[107]  F. Walker,et al.  Axial ligand complexes of the Rhodnius nitrophorins: reduction potentials, binding constants, EPR spectra, and structures of the 4-iodopyrazole and imidazole complexes of NP4 , 2004, JBIC Journal of Biological Inorganic Chemistry.

[108]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[109]  P. S. Ho,et al.  Effect of sequence on the conformation of DNA holliday junctions. , 2003, Biochemistry.

[110]  Martin Stahl,et al.  Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. , 2009, European journal of medicinal chemistry.

[111]  Rainer Wilcken,et al.  Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition , 2012, Proceedings of the National Academy of Sciences.

[112]  Barbara Kirchner,et al.  Addressing Methionine in Molecular Design through Directed Sulfur-Halogen Bonds. , 2011, Journal of chemical theory and computation.

[113]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[114]  M. Hilgers,et al.  Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design. , 2013, Journal of medicinal chemistry.

[115]  P Shing Ho,et al.  Directing macromolecular conformation through halogen bonds , 2007, Proceedings of the National Academy of Sciences.

[116]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[117]  A. Joerger,et al.  Principles and applications of halogen bonding in medicinal chemistry and chemical biology. , 2013, Journal of medicinal chemistry.

[118]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[119]  Juhua Xu,et al.  Application of a new bicyclic triaminophosphine ligand in Pd-catalyzed Buchwald-Hartwig amination reactions of aryl chlorides, bromides, and iodides. , 2003, The Journal of organic chemistry.

[120]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[121]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[122]  John K. Stille,et al.  The Palladium‐Catalyzed Cross‐Coupling Reactions of Organotin Reagents with Organic Electrophiles [New Synthetic Methods (58)] , 1986 .

[123]  Peter Politzer,et al.  Expansion of the σ-hole concept , 2009, Journal of molecular modeling.

[124]  Peng Zhou,et al.  Fluorine Bonding - How Does It Work In Protein-Ligand Interactions? , 2009, J. Chem. Inf. Model..

[125]  J. Christensen,et al.  Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). , 2011, Journal of medicinal chemistry.

[126]  Jindřich Fanfrlík,et al.  Halogen bond tunability II: the varying roles of electrostatic and dispersion contributions to attraction in halogen bonds , 2013, Journal of Molecular Modeling.

[127]  Patric Schyman,et al.  Treatment of Halogen Bonding in the OPLS-AA Force Field; Application to Potent Anti-HIV Agents. , 2012, Journal of chemical theory and computation.

[128]  Z Dauter,et al.  Novel approach to phasing proteins: derivatization by short cryo-soaking with halides. , 2000, Acta crystallographica. Section D, Biological crystallography.

[129]  S. Cutler,et al.  Identification and Mechanism of ABA Receptor Antagonism , 2010, Nature Structural &Molecular Biology.

[130]  M Karplus,et al.  HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.

[131]  Pierangelo Metrangolo,et al.  Halogen bonding in halocarbon-protein complexes: a structural survey. , 2011, Chemical Society reviews.

[132]  Corey Strickland,et al.  Enhanced FTase activity achieved via piperazine interaction with catalytic zinc. , 2006, Bioorganic & medicinal chemistry letters.

[133]  H. Stoll,et al.  Systematically convergent basis sets with relativistic pseudopotentials. II. Small-core pseudopotentials and correlation consistent basis sets for the post-d group 16–18 elements , 2003 .

[134]  Thomas Lampe,et al.  Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[135]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[136]  Pierre Koch,et al.  Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. , 2012, Journal of Medicinal Chemistry.

[137]  Timothy Clark,et al.  Halogen bonding and other σ-hole interactions: a perspective. , 2013, Physical chemistry chemical physics : PCCP.

[138]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[139]  E. Arnold,et al.  Fragment screening and HIV therapeutics. , 2012, Topics in current chemistry.

[140]  Corey Strickland,et al.  Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. , 2012, Topics in current chemistry.

[141]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[142]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[143]  Anna Vulpetti,et al.  Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. , 2009, Journal of the American Chemical Society.

[144]  C. Nájera,et al.  The Sonogashira reaction: a booming methodology in synthetic organic chemistry. , 2007, Chemical reviews.

[145]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[146]  Martin Lepšík,et al.  Modulation of aldose reductase inhibition by halogen bond tuning. , 2013, ACS chemical biology.

[147]  G. Sheldrick,et al.  A magic triangle for experimental phasing of macromolecules. , 2008, Acta crystallographica. Section D, Biological crystallography.

[148]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[149]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[150]  A. Fersht,et al.  Structural basis for understanding oncogenic p53 mutations and designing rescue drugs , 2006, Proceedings of the National Academy of Sciences.

[151]  C. Prives,et al.  Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay , 1998, Oncogene.

[152]  P. Metrangolo,et al.  Halogen bonding: a paradigm in supramolecular chemistry. , 2001, Chemistry.

[153]  Alan R. Fersht,et al.  Small molecule induced reactivation of mutant p53 in cancer cells , 2013, Nucleic acids research.

[154]  A. Fersht,et al.  Structure–function–rescue: the diverse nature of common p53 cancer mutants , 2007, Oncogene.

[155]  J. Poznański,et al.  Halogen bonding at the ATP binding site of protein kinases: preferred geometry and topology of ligand binding. , 2013, Biochimica et biophysica acta.

[156]  A. Fersht,et al.  Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.

[157]  F. Weigend,et al.  Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. , 2005, Physical chemistry chemical physics : PCCP.

[158]  Timothy Clark,et al.  Polarization-induced σ-holes and hydrogen bonding , 2012, Journal of Molecular Modeling.

[159]  Daniel A. Erlanson,et al.  Fragment‐Based Drug Discovery. , 2004 .

[160]  Joel H. Hildebrand,et al.  A Spectrophotometric Investigation of the Interaction of Iodine with Aromatic Hydrocarbons , 1949 .

[161]  S. Buchwald,et al.  Rational Development of Practical Catalysts for Aromatic Carbon—Nitrogen Bond Formation , 1999 .

[162]  F. Diederich,et al.  Book review: Metal-catalyzed cross-coupling reactions. F. Diederich and P. J. Stang (eds) Wiley–VCH, Weinheim, 1998. xxi + 517 pages, £85 ISBN 3–527–29421–X , 1998 .